Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Glioblastoma Therapy in the Age of Molecular Medicine.

Geraldo LHM, Garcia C, da Fonseca ACC, Dubois LGF, de Sampaio E Spohr TCL, Matias D, de Camargo Magalhães ES, do Amaral RF, da Rosa BG, Grimaldi I, Leser FS, Janeiro JM, Macharia L, Wanjiru C, Pereira CM, Moura-Neto V, Freitas C, Lima FRS.

Trends Cancer. 2019 Jan;5(1):46-65. doi: 10.1016/j.trecan.2018.11.002. Epub 2018 Dec 7. Review.

PMID:
30616755
2.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
3.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
4.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

5.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

6.

Recent advances and future of immunotherapy for glioblastoma.

Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. doi: 10.1080/14712598.2016.1212012. Epub 2016 Jul 27. Review.

7.

Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK.

J Clin Oncol. 2015 Apr 1;33(10):1197-213. doi: 10.1200/JCO.2014.55.9575. Epub 2015 Feb 23.

8.
9.

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M.

Oncotarget. 2013 Sep;4(9):1527-46.

10.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
11.

Current status of antiangiogenic therapies for glioblastomas.

Arrillaga-Romany I, Reardon DA, Wen PY.

Expert Opin Investig Drugs. 2014 Feb;23(2):199-210. doi: 10.1517/13543784.2014.856880. Epub 2013 Dec 10. Review.

PMID:
24320142
12.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
13.

Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.

Seystahl K, Gramatzki D, Roth P, Weller M.

Expert Opin Pharmacother. 2016 Jun;17(9):1259-70. doi: 10.1080/14656566.2016.1176146. Epub 2016 Apr 21. Review.

14.

Advances in immunotherapeutic research for glioma therapy.

Miyauchi JT, Tsirka SE.

J Neurol. 2018 Apr;265(4):741-756. doi: 10.1007/s00415-017-8695-5. Epub 2017 Dec 5. Review.

PMID:
29209782
15.

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.

PMID:
26454859
16.

Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.

Shirai K, Siedow MR, Chakravarti A.

J Oncol. 2012;2012:193436. doi: 10.1155/2012/193436. Epub 2011 Jul 14.

17.

Antiangiogenic Therapy of High-Grade Gliomas.

Jo J, Wen PY.

Prog Neurol Surg. 2018;31:180-199. doi: 10.1159/000467379. Epub 2018 Jan 25. Review.

PMID:
29393186
18.

Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.

Okonogi N, Shirai K, Oike T, Murata K, Noda SE, Suzuki Y, Nakano T.

Anticancer Res. 2015 Mar;35(3):1229-35. Review.

PMID:
25750269
19.

Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme.

Kochar AS, Madhavan M, Manjila S, Scoco A, Belle VK, Geertman RT.

Asian J Neurosurg. 2018 Jul-Sep;13(3):546-554. doi: 10.4103/ajns.AJNS_266_16. Review.

20.

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE 2nd, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH.

PLoS One. 2014 Apr 10;9(4):e94281. doi: 10.1371/journal.pone.0094281. eCollection 2014.

Supplemental Content

Support Center